首页> 外国专利> Treating cells genetically/epigenetically to treat diseases, involves contacting nucleus of to-be-treated cell with genetic reprogramming medium having natural cytoplasm of genetic reprogramming cell, to modify biological age

Treating cells genetically/epigenetically to treat diseases, involves contacting nucleus of to-be-treated cell with genetic reprogramming medium having natural cytoplasm of genetic reprogramming cell, to modify biological age

机译:从遗传/表观上治疗细胞以治疗疾病,涉及使待治疗细胞的核与具有遗传重编程细胞天然细胞质的遗传重编程培养基接触,以改变生物学年龄

摘要

Genetic and epigenetic treatment process for to-be-treated cells, involves supplying at least one to-be-treated cell, supplying a genetic reprogramming medium (GRM) comprising at least natural cytoplasm of at least one genetic reprogramming cell (GRC) and/or synthetic cytoplasm, and bringing at least portion of at least one nucleus of one or more to-be-treated cell into contact with the GRM to modify the biological age and/or to repair the one or more to-be-treated cell. Genetic and epigenetic treatment process for to-be-treated cells, involves supply of at least one to-be-treated cell, supplying a genetic reprogramming medium (GRM) comprising at least natural cytoplasm of at least one genetic reprogramming cell (GRC) and/or synthetic cytoplasm, and bringing at least portion of at least one nucleus of at least one to-be-treated cell into contact with the GRM to modify the biological age and/or to repair the to-be-treated cell. Process for genetic and epigenetic treatment, involves use of at least one genetic reprogramming cell and at least one differentiated cell for fabrication of at least one regenerated differentiated cell capable of being reimplanted to treat various pathologies, diseases and/or tissue insufficiencies, involves supplying at least one GRC formed of an oocyte or an embryonic cell, supplying at least one differentiated cell, preferably completely removing the nucleus from the GRC, removing and transferring the nucleus of a differentiated cell into the GRC, extracting the nucleus of the differentiated cell transferred into the GRC, before the end of its first mitosis, and introducing the nucleus of the extracted differentiated cell into a differentiated cell, preferably from which its nucleus has been removed and preferably autologous, so as to form a regenerated differentiated cell, multiplying the regenerated differentiated cell. Independent claims are included for: (1) cancer treatment process, involves removal of at least one hematopoietic cell at the bone marrow or its periphery, supplying GRM, putting at least a portion of a nucleus of removed hematopoietic cell into contact with the GRM, separating at least portion of a nucleus of a removed hematopoietic cell from the GRM, introducing at least the portion of a nucleus of a hematopoietic cell thus separated in an hematopoietic receiving cell, preferably from which its nucleus has been removed, preferably autologous, to rejuvenate the hematopoietic receiving cell, multiplying the rejuvenated receiving cell in vitro, and reinjecting the rejuvenated cells to combat cancer; (2) system (S1) for genetic and epigenetic treatment process for to-be-treated cells, comprising at least one to-be-treated cell, GRM, and unit for bringing at least a portion of at least one nucleus of to-be-treated cell into contact with the GRM, to modify the biological age and/or repair the to-be-treated cell; and (3) system (S2) for genetic regeneration of differentiated cells, comprising at least one differentiated cell, unit for cell reprogramming, comprising at least one GRC formed of an oocytes or an embryonic cell, unit for removing the nucleus of at least one GRC, preferably completely, unit for removing and transferring the nucleus of a differentiated cell into a corresponding GRC, unit for extracting the transferred nucleus of the differentiated cell from the GRC, before the end of its first mitosis, and unit for introducing the nucleus of the extracted differentiated cell into a differentiated receiving cell, preferably from which its nucleus has been removed and preferably autologous, the receiving cell then being a regenerated cell capable of multiplying, the resulting tissue being designed to be positioned within a to be-regenerated tissue. ACTIVITY : Cytostatic; Antiulcer; Antiarthritic; Osteopathic; Hepatotropic; Cardiant. No biological data given. MECHANISM OF ACTION : Cell therapy.
机译:待处理细胞的遗传和表观遗传处理过程包括提供至少一种待处理细胞,提供包括至少一种遗传重编程细胞(GRC)的至少天然细胞质的遗传重编程培养基(GRM)和/使一个或多个待处理细胞的至少一个核的至少一部分与GRM接触,以改变生物学年龄和/或修复一个或多个待处理细胞。待处理细胞的遗传和表观遗传处理过程包括提供至少一种待处理细胞,提供包含至少一种遗传重编程细胞(GRC)的至少天然细胞质的遗传重编程培养基(GRM)和/或合成细胞质,并使至少一种待治疗细胞的至少一个核的至少一部分与GRM接触,以改变生物学年龄和/或修复待治疗细胞。遗传和表观遗传学治疗的方法,涉及使用至少一种遗传重编程细胞和至少一种分化细胞来制造至少一种能够再植入以治疗各种病理学,疾病和/或组织功能不全的再生分化细胞,包括在由卵母细胞或胚胎细胞形成的至少一个GRC,提供至少一个分化的细胞,最好从GRC完全去除细胞核,将分化细胞的细胞核去除并转移到GRC中,提取转移到细胞中的分化细胞的细胞核GRC,在其第一次有丝分裂结束之前,将提取的分化细胞的细胞核引入分化细胞,优选从中除去细胞核,最好是自体的,从而形成再生的分化细胞,使再生的分化细胞倍增细胞。包括以下独立权利要求:(1)癌症治疗过程,涉及去除骨髓或其周围的至少一个造血细胞,供应GRM,使至少一部分已去除的造血细胞核与GRM接触,将分离的造血细胞的至少一部分细胞核与GRM分离,从而将如此分离的造血细胞的细胞核的至少一部分引入造血细胞,优选从其细胞核中去除,优选自体,以使其恢复活力造血接受细胞,在体外增殖再生的接受细胞,并重新注入再生的细胞以对抗癌症。 (2)用于待处理细胞的遗传和表观遗传处理过程的系统(S1),包括至少一个待处理细胞,GRM和用于使至少一个至少一个核的一部分进入的单元-待处理细胞与GRM接触,以改变生物学年龄和/或修复待处理细胞; (3)用于分化细胞的遗传再生的系统(S2),其包括至少一种分化细胞,用于细胞重编程的单元,其包含至少一种由卵母细胞或胚胎细胞形成的GRC,用于去除至少一种细胞核的单元。 GRC,最好是完全的,用于将分化细胞的核移出并转移到相应的GRC中的单元,用于在GRC第一次有丝分裂结束之前从GRC提取分化细胞的转移核的单元,以及用于引入GRC的细胞核的单元。将提取的分化细胞转变为分化的接受细胞,优选从其细胞核中除去并优选自体,然后该接受细胞为能够繁殖的再生细胞,将所得组织设计为定位在待再生组织内。活动:细胞抑制;抗溃疡;抗关节炎整骨;肝卡迪恩没有给出生物学数据。作用机理:细胞疗法。

著录项

  • 公开/公告号FR2893630A1

    专利类型

  • 公开/公告日2007-05-25

    原文格式PDF

  • 申请/专利权人 ZACOUTO FRED;

    申请/专利号FR20050053533

  • 发明设计人 ZACOUTO FRED;

    申请日2005-11-21

  • 分类号C12N5/075;

  • 国家 FR

  • 入库时间 2022-08-21 20:26:54

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号